{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T07:33:54Z","timestamp":1773300834178,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2017,2,27]],"date-time":"2017-02-27T00:00:00Z","timestamp":1488153600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1038\/aps.2016.159","type":"journal-article","created":{"date-parts":[[2017,2,27]],"date-time":"2017-02-27T10:01:37Z","timestamp":1488189697000},"page":"638-650","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Synthesis of the novel PARP-1 inhibitor AG-690\/11026014 and its protective effects on angiotensin II-induced mouse cardiac remodeling"],"prefix":"10.1038","volume":"38","author":[{"given":"Guo-shuai","family":"Feng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cui-ge","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuo-ming","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pan-xia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lan-lan","family":"Lou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shao-rui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei-qing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,2,27]]},"reference":[{"key":"BFaps2016159_CR1","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/S0735-1097(99)00630-0","volume":"35","author":"JN Cohn","year":"2000","unstructured":"Cohn JN, Ferrari R, Sharpe N . Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 2000; 35: 569\u201382.","journal-title":"J Am Coll Cardiol"},{"key":"BFaps2016159_CR2","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1161\/01.CIR.83.6.1849","volume":"83","author":"K Weber","year":"1991","unstructured":"Weber K, Brilla CG . Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 1991; 83: 1849\u201365.","journal-title":"Circulation"},{"key":"BFaps2016159_CR3","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1113\/expphysiol.2005.031096","volume":"90","author":"MJ Huentelman","year":"2005","unstructured":"Huentelman MJ, Grobe JL, Vazquez J, Stewart JM, Mecca AP, Katovich MJ, et al. Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats. Exp Physiol 2005; 90: 783\u201390.","journal-title":"Exp Physiol"},{"key":"BFaps2016159_CR4","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1161\/01.CIR.103.6.789","volume":"103","author":"D-S Lim","year":"2001","unstructured":"Lim D-S, Lutucuta S, Bachireddy P, Youker K, Evans A, Entman M, et al. Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation 2001; 103: 789\u201391.","journal-title":"Circulation"},{"key":"BFaps2016159_CR5","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1073\/pnas.97.2.931","volume":"97","author":"P Paradis","year":"2000","unstructured":"Paradis P, Dali-Youcef N, Paradis FW, Thibault G, Nemer M . Overexpression of angiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling. Proc Natl Acad Sci U S A 2000; 97: 931\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"BFaps2016159_CR6","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1161\/01.CIR.104.3.346","volume":"104","author":"S Ichihara","year":"2001","unstructured":"Ichihara S, Senbonmatsu T, Price E, Ichiki T, Gaffney FA, Inagami T . Angiotensin II type 2 receptor is essential for left ventricular hypertrophy and cardiac fibrosis in chronic angiotensin II-induced hypertension. Circulation 2001; 104: 346\u201351.","journal-title":"Circulation"},{"key":"BFaps2016159_CR7","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1002\/med.21300","volume":"34","author":"S Xu","year":"2014","unstructured":"Xu S, Bai P, Little PJ, Liu P . Poly (ADP-ribose) polymerase 1 (PARP1) in atherosclerosis: from molecular mechanisms to therapeutic implications. Med Res Rev 2014; 34: 644\u201375.","journal-title":"Med Res Rev"},{"key":"BFaps2016159_CR8","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nrm1963","volume":"7","author":"V Schreiber","year":"2006","unstructured":"Schreiber V, Dantzer F, Ame JC, De Murcia G . Poly (ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol 2006; 7: 517\u201328.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"BFaps2016159_CR9","doi-asserted-by":"crossref","first-page":"6048","DOI":"10.1016\/S0021-9258(17)38491-0","volume":"261","author":"H Suzuki","year":"1986","unstructured":"Suzuki H, Quesada P, Farina B, Leone E . In vitro poly (ADP-ribosyl) ation of seminal ribonuclease. J Biol Chem 1986; 261: 6048\u201355.","journal-title":"J Biol Chem"},{"key":"BFaps2016159_CR10","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1358\/mf.2006.28.10.1037495","volume":"28","author":"P Balakumar","year":"2006","unstructured":"Balakumar P, Singh M . Possible role of poly(ADP-ribose) polymerase in pathological and physiological cardiac hypertrophy. Methods Find Exp Clin Pharmacol 2006; 28: 683\u20139.","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"BFaps2016159_CR11","doi-asserted-by":"publisher","first-page":"H1545","DOI":"10.1152\/ajpheart.01124.2005","volume":"291","author":"JB Pillai","year":"2006","unstructured":"Pillai JB, Gupta M, Rajamohan SB, Lang R, Raman J, Gupta MP . Poly (ADP-ribose) polymerase-1-deficient mice are protected from angiotensin II-induced cardiac hypertrophy. Am J Physiol Heart Circ Physiol 2006; 291: H1545\u2013H53.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"BFaps2016159_CR12","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1093\/cvr\/cvn264","volume":"81","author":"D Huang","year":"2009","unstructured":"Huang D, Yang C, Wang Y, Liao Y, Huang K . PARP-1 suppresses adiponectin expression through poly (ADP-ribosyl) ation of PPAR\u03b3 in cardiac fibroblasts. Cardiovasc Res 2009; 81: 98\u2013107.","journal-title":"Cardiovasc Res"},{"key":"BFaps2016159_CR13","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1124\/jpet.300.3.862","volume":"300","author":"P Pacher","year":"2002","unstructured":"Pacher P, Liaudet L, Bai P, Virag L, Mabley JG, Hasko G, et al. Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure. J Pharmacol Exp Ther 2002; 300: 862\u20137.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFaps2016159_CR14","doi-asserted-by":"publisher","first-page":"H486","DOI":"10.1152\/ajpheart.00437.2004","volume":"288","author":"JB Pillai","year":"2005","unstructured":"Pillai JB, Russell HM, Raman J, Jeevanandam V, Gupta MP . Increased expression of poly(ADP-ribose) polymerase-1 contributes to caspase-independent myocyte cell death during heart failure. Am J Physiol Heart Circ Physiol 2005; 288: H486\u201396.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"BFaps2016159_CR15","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1093\/cvr\/cvp144","volume":"83","author":"E Bartha","year":"2009","unstructured":"Bartha E, Solti I, Kereskai L, Lantos J, Plozer E, Magyar K, et al. PARP inhibition delays transition of hypertensive cardiopathy to heart failure in spontaneously hypertensive rats. Cardiovasc Res 2009; 83: 501\u201310.","journal-title":"Cardiovasc Res"},{"key":"BFaps2016159_CR16","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.yjmcc.2006.03.427","volume":"41","author":"A Palfi","year":"2006","unstructured":"Palfi A, Toth A, Hanto K, Deres P, Szabados E, Szereday Z, et al. PARP inhibition prevents postinfarction myocardial remodeling and heart failure via the protein kinase C\/glycogen synthase kinase-3\u03b2 pathway. J Mol Cell Cardiol 2006; 41: 149\u201359.","journal-title":"J Mol Cell Cardiol"},{"key":"BFaps2016159_CR17","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1161\/hh0102.102657","volume":"90","author":"G Szab\u00f3","year":"2002","unstructured":"Szab\u00f3 G, B\u00e4hrle S, Stumpf N, Sonnenberg K, Szab\u00f3 \u00c9, Pacher P, et al. Poly (ADP-ribose) polymerase inhibition reduces reperfusion injury after heart transplantation. Circ Res 2002; 90: 100\u20136.","journal-title":"Circ Res"},{"key":"BFaps2016159_CR18","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.mce.2014.05.010","volume":"392","author":"M Liu","year":"2014","unstructured":"Liu M, Li Z, Chen GW, Li ZM, Wang LP, Ye JT, et al. AG-690\/11026014, a novel PARP-1 inhibitor, protects cardiomyocytes from Ang II-induced hypertrophy. Mol Cell Endocrinol 2014; 392: 14\u201322.","journal-title":"Mol Cell Endocrinol"},{"key":"BFaps2016159_CR19","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.tox.2005.06.023","volume":"214","author":"SH Koh","year":"2005","unstructured":"Koh SH, Chang DI, Kim HT, Kim J, Kim MH, Kim KS, et al. Effect of 3-aminobenzamide, PARP inhibitor, on matrix metalloproteinase-9 level in plasma and brain of ischemic stroke model. Toxicology 2005; 214: 131\u20139.","journal-title":"Toxicology"},{"key":"BFaps2016159_CR20","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2174\/157340606775197697","volume":"2","author":"PA Nguewa","year":"2006","unstructured":"Nguewa PA, Fuertes MA, Cepeda V, Alonso C, Quevedo C, Soto M, et al. Poly(ADP-ribose) polymerase-1 inhibitor 3-aminobenzamide enhances apoptosis induction by platinum complexes in cisplatin-resistant tumor cells. Med Chem 2006; 2: 47\u201353.","journal-title":"Med Chem"},{"key":"BFaps2016159_CR21","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1021\/pr050456l","volume":"5","author":"SG Zhou","year":"2006","unstructured":"Zhou SG, Zhou SF, Huang HQ, Chen JW, Huang M, Liu PQ . Proteomic analysis of hypertrophied myocardial protein patterns in renovascularly hypertensive and spontaneously hypertensive rats. J Proteome Res 2006; 5: 2901\u20138.","journal-title":"J Proteome Res"},{"key":"BFaps2016159_CR22","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/j.1476-5381.2012.01903.x","volume":"168","author":"SS Yu","year":"2013","unstructured":"Yu SS, Cai Y, Ye JT, Pi RB, Chen SR, Liu PQ, et al. Sirtuin 6 protects cardiomyocytes from hypertrophy in vitro via inhibition of NF-kappaB-dependent transcriptional activity. Br J Pharmacol 2013; 168: 117\u201328.","journal-title":"Br J Pharmacol"},{"key":"BFaps2016159_CR23","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1096\/fj.04-1841rev","volume":"18","author":"AI Scovassi","year":"2004","unstructured":"Scovassi AI . Mitochondrial poly(ADP-ribosylation): from old data to new perspectives. FASEB J 2004; 18: 1487\u20138.","journal-title":"FASEB J"},{"key":"BFaps2016159_CR24","doi-asserted-by":"publisher","first-page":"18426","DOI":"10.1074\/jbc.M301295200","volume":"278","author":"L Du","year":"2003","unstructured":"Du L, Zhang X, Han YY, Burke NA, Kochanek PM, Watkins SC, et al. Intra-mitochondrial poly(ADP-ribosylation) contributes to NAD+ depletion and cell death induced by oxidative stress. J Biol Chem 2003; 278: 18426\u201333.","journal-title":"J Biol Chem"},{"key":"BFaps2016159_CR25","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1101\/gad.183509.111","volume":"26","author":"X Luo","year":"2012","unstructured":"Luo X, Kraus WL . On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1. Genes Dev 2012; 26: 417\u201332.","journal-title":"Genes Dev"},{"key":"BFaps2016159_CR26","first-page":"H736","volume":"292","author":"JL Grobe","year":"2007","unstructured":"Grobe JL, Mecca AP, Lingis M, Shenoy V, Bolton TA, Machado JM, et al. Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1\u20137). Am J Physiol 2007; 292: H736\u2013H42.","journal-title":"Am J Physiol"},{"key":"BFaps2016159_CR27","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1002\/hep.26763","volume":"59","author":"P Mukhopadhyay","year":"2014","unstructured":"Mukhopadhyay P, Rajesh M, Cao Z, Horvath B, Park O, Wang H, et al. Poly (ADP-ribose) polymerase-1 is a key mediator of liver inflammation and fibrosis. Hepatology (Baltimore, Md) 2014; 59: 1998\u20132009.","journal-title":"Hepatology (Baltimore, Md)"},{"key":"BFaps2016159_CR28","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ajpath.2012.09.004","volume":"182","author":"B Hu","year":"2013","unstructured":"Hu B, Wu Z, Hergert P, Henke CA, Bitterman PB, Phan SH . Regulation of myofibroblast differentiation by poly(ADP-ribose) polymerase 1. Am J Pathol 2013; 182: 71\u201383.","journal-title":"Am J Pathol"},{"key":"BFaps2016159_CR29","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.yjmcc.2008.10.019","volume":"46","author":"D Huang","year":"2009","unstructured":"Huang D, Wang Y, Yang C, Liao Y, Huang K . Angiotensin II promotes poly(ADP-ribosyl)ation of c-Jun\/c-Fos in cardiac fibroblasts. J Mol Cell Cardiol 2009; 46: 25\u201332.","journal-title":"J Mol Cell Cardiol"},{"key":"BFaps2016159_CR30","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1016\/j.ijcard.2012.06.050","volume":"167","author":"Y Wang","year":"2013","unstructured":"Wang Y, Wang L, Zhang F, Zhang C, Deng S, Wang R, et al. Inhibition of PARP prevents angiotensin II-induced aortic fibrosis in rats. Int J Cardiol 2013; 167: 2285\u201393.","journal-title":"Int J Cardiol"},{"key":"BFaps2016159_CR31","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1210\/me.2007-0079","volume":"21","author":"H Yamamoto","year":"2007","unstructured":"Yamamoto H, Schoonjans K, Auwerx J . Sirtuin functions in health and disease. Mol Endocrinol 2007; 21: 1745\u201355.","journal-title":"Mol Endocrinol"},{"key":"BFaps2016159_CR32","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.tem.2016.04.015","volume":"27","author":"S Bindu","year":"2016","unstructured":"Bindu S, Pillai VB, Gupta MP . Role of sirtuins in regulating pathophysiology of the heart. Trends Endocrinol Metab 2016; 27: 563\u201373.","journal-title":"Trends Endocrinol Metab"},{"key":"BFaps2016159_CR33","doi-asserted-by":"publisher","first-page":"3404","DOI":"10.1093\/eurheartj\/ehv290","volume":"36","author":"S Winnik","year":"2015","unstructured":"Winnik S, Auwerx J, Sinclair DA, Matter CM . Protective effects of sirtuins in cardiovascular diseases: from bench to bedside. Eur Heart J 2015; 36: 3404\u201312.","journal-title":"Eur Heart J"},{"key":"BFaps2016159_CR34","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/ajh.2009.228","volume":"23","author":"SJ Thandapilly","year":"2010","unstructured":"Thandapilly SJ, Wojciechowski P, Behbahani J, Louis XL, Yu L, Juric D, et al. Resveratrol prevents the development of pathological cardiac hypertrophy and contractile dysfunction in the SHR without lowering blood pressure. Am J Hypertens 2010; 23: 192\u20136.","journal-title":"Am J Hypertens"},{"key":"BFaps2016159_CR35","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ijcard.2015.12.008","volume":"205","author":"D Cappetta","year":"2016","unstructured":"Cappetta D, Esposito G, Piegari E, Russo R, Ciuffreda LP, Rivellino A, et al. SIRT1 activation attenuates diastolic dysfunction by reducing cardiac fibrosis in a model of anthracycline cardiomyopathy. Int J Cardiol 2016; 205: 99\u2013110.","journal-title":"Int J Cardiol"},{"key":"BFaps2016159_CR36","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1002\/bies.10317","volume":"25","author":"J Zhang","year":"2003","unstructured":"Zhang J . Are poly(ADP-ribosyl)ation by PARP-1 and deacetylation by Sir2 linked? Bioessays 2003; 25: 808\u201314.","journal-title":"Bioessays"},{"key":"BFaps2016159_CR37","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.cmet.2011.03.004","volume":"13","author":"P Bai","year":"2011","unstructured":"Bai P, Cant\u00f3 C, Oudart H, Bruny\u00e1nszki A, Cen Y, Thomas C, et al. PARP-1 inhibition increases mitochondrial metabolism through SIRT1 activation. Cell Metab 2011; 13: 461\u20138.","journal-title":"Cell Metab"},{"key":"BFaps2016159_CR38","doi-asserted-by":"publisher","first-page":"4116","DOI":"10.1128\/MCB.00121-09","volume":"29","author":"SB Rajamohan","year":"2009","unstructured":"Rajamohan SB, Pillai VB, Gupta M, Sundaresan NR, Birukov KG, Samant S, et al. SIRT1 promotes cell survival under stress by deacetylation-dependent deactivation of poly (ADP-ribose) polymerase 1. Mol Cell Biol 2009; 29: 4116\u201329.","journal-title":"Mol Cell Biol"},{"key":"BFaps2016159_CR39","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1002\/med.21300","volume":"34","author":"S Xu","year":"2014","unstructured":"Xu S, Bai P, Little PJ, Liu P . Poly(ADP-ribose) polymerase 1 (PARP1) in atherosclerosis: from molecular mechanisms to therapeutic implications. Med Res Rev 2014; 34: 644\u201375.","journal-title":"Med Res Rev"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/aps2016159.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/aps2016159","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/aps.2016.159","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/aps2016159.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:34:09Z","timestamp":1684413249000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/aps2016159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,27]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["BFaps2016159"],"URL":"https:\/\/doi.org\/10.1038\/aps.2016.159","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,27]]},"assertion":[{"value":"26 September 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}